TNF and demyelinating disease: In addition to corticosteroids and 5-aminosalicylates, the expanding therapeutic landscape of IBD includes biologics and small molecules that modulate immune pathways also implicated in demyelinating disease, including TNF, JAK-STAT, and IL-12/23 signaling.10